Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CLBTBearishLegalnews

High materiality7/10

Kaplan Fox Investigation Highlights Cellebrite CLBT Securities Risk After ARR Miss

Oct 2, 2026, 2:20 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The disclosure of a securities investigation, plus prior ARR miss and CEO change, commonly increases downside risk and reduces confidence in near-term cash flow visibility; price typically drifts lower until clarity on findings emerges, as seen in prior CLBT volatility after negative results.

AI summary

What happened, with direct paths to the underlying reporting

Kaplan Fox & Kilsheimer LLP announced an investigation into potential securities violations at Cellebrite after its Q2 results showed ARR of $507.8 million and a mid-point ARR guidance cut of about $15 million. The abrupt CEO change to Shiv Ramji and a 29% stock drop heighten investor concern over Cellebrite's growth trajectory and governance, potentially weighing on CLBT near-term sentiment.

Kaplan Fox investigates potential securities violations at Cellebrite (CLBT).
Q2 ARR: $507.8M; guidance cut by ~$15M at midpoint.
CEO Tom Hogan replaced by Shiv Ramji; stock fell 29% on Aug 13, 2026.
Foreign entity permit delays cloud deals, pressuring ARR timing.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.